Marks & Clerk expertise cited in American Biotech publication, Endpoints News

An in­tel­lec­tu­al prop­er­ty law firm says that re­cent guid­ance from the UK’s Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency hints at the pos­si­bil­i­ty of the agency al­low­ing ap­provals from oth­er reg­u­la­tors, in­clud­ing pos­si­bly the US FDA, to play a role in UK reg­u­la­to­ry process­es. Marks & Clerk, based out of Lon­don, wrote in a blog post that guid­ance from the UK’s reg­u­la­to­ry agency from late Jan­u­ary is pro­vid­ing more con­text in­to po­ten­tial in­ter­na­tion­al col­lab­o­ra­tion with oth­er reg­u­la­tors. How that would come about is af­ter the UK’s “Re­liance Pro­ce­dure” — a way to en­sure pa­tients in Great Britain post-Brex­it could still ac­cess new med­i­cines — ex­pires.